by Massimo Sandal (Agenzia Zoe)
Takeaway messages
-
A 2.5 year ibrutinib plus FCR (iFCR) therapy shows PFS and OS of 97% and 99% after a >40 months follow-up on young CLL patients.
Why this matters
ASH 2021 — Ibrutinib plus FCR as first-line therapy for younger patients with CLL
Daniela Ovadia — Agenzia Zoe
|
Conference Report
|
16 December 2021
Register or log in to read more
Registration is free and easy, giving you complete access to all Univadis content.
Create a Free Account I have an account
